The guidance change marks the latest adjustment Novo has made to its 2025 outlook as the company battles a changing market.

Agentic AI was a point of emphasis on the first day of the 2025 Veeva Commercial summit held in Madrid, Spain.

Avant Technologies and SGAustria have announced a joint venture (JV) and licence agreement to advance a therapy for diabetes ...

Here are three important regulatory changes affecting parenteral packaging that pharmaceutical companies need to be aware of ...

Ensuring fair drug pricing was a key promise of Sri Lanka’s government’s election manifesto, and that promise is finally ...

Expanding Access to Lyophilized Therapies: Reunite removes reliance on vial kits and manual reconstitution, making ...

ADCs remain à la mode in the oncology sector, with Merck & Co (MSD) tying up another deal to advance its pipeline in the ...

Both companies have upped their offers for Metsera amid a bidding war, but Novo Nordisk comes armed with an extra $1.9bn.

AmacaThera has entered into an exclusive worldwide licensing agreement with Pacira BioSciences for up to $230m for AMT-143, an investigational long-acting non-opioid anaesthetic.

Boehringer Ingelheim and CDR-Life have announced a worldwide licencing agreement for the development of CDR111, an antibody-based molecule targeting autoimmune conditions.